Literature DB >> 21601486

Ray reduction of the foot in the treatment of macrodactyly and review of the literature.

M Jenda Hop1, Jan Jaap van der Biezen.   

Abstract

Macrodactyly of the foot is a rare disorder characterized by enlargement of the soft tissue and osseous elements of the foot that impedes the development of normal function and gait. Despite the morbidity associated with this condition, many surgeons are reluctant to perform surgical reduction. In the present report, we describe 3 pediatric patients with pedal macrodactyly, who underwent surgical correction consisting of amputation of the most enlarged ray, reduction of the adjacent rays, and ray transposition, combined with debulking of soft tissues. All 3 patients subsequently developed a normal gait and were able to wear normal, or minimally adjusted, shoes. We advocate early surgical treatment of macrodactyly of the foot to enhance the development of normal function and gait.
Copyright © 2011 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601486     DOI: 10.1053/j.jfas.2011.04.011

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  3 in total

1.  Isolated Acquired Macrodactyly of the Left Fourth Toe.

Authors:  Leon Alexander; Ahmed Mohamed H El Kazzaz; Michael Schenker
Journal:  Cureus       Date:  2021-01-12

2.  Island nail flap in the treatment of foot macrodactyly of the first ray in children: report of two cases.

Authors:  Francisco Javier Downey-Carmona; Araceli Lagares; David Farrington-Rueda; José Lirola-Criado
Journal:  J Child Orthop       Date:  2015-08-04       Impact factor: 1.548

3.  Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1.

Authors:  Bin Sun; Yongkang Jiang; Hengqing Cui; Xia Fang; Gang Han; Xinyi Dai; Shengbo Zhou; Hailei Mao; Bin Wang
Journal:  Cell Death Dis       Date:  2020-07-30       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.